Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KB105

Gene therapy · Gene replacement · developed by Krystal Biotech

Phase 2 Most advanced trial (none active)
KRYS Developer
1 Registered trials

What is KB105?

KB105 is a replication-defective, non-integrating HSV-1 vector carrying the TGM1 gene, formulated as a topical gel. It is designed to deliver TGM1, which encodes transglutaminase 1, to the skin in autosomal recessive ichthyosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Mechanism
Gene replacement
Therapy area
Dermatology
Developer
Krystal Biotech, Inc. (KRYS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7RJ7NSG7A0

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05735158 Phase 2 Autosomal Recessive Ichthyosis Unknown KRYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autosomal Recessive Ichthyosis

More from Krystal Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.

Follow KRYS, the company behind KB105

See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KRYS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.